Myriad Genetics (MYGN) Stock Forecast & Price Target $6.02 +0.20 (+3.44%) Closing price 04:00 PM EasternExtended Trading$5.99 -0.03 (-0.55%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Myriad Genetics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 8 Analyst RatingsSell1Hold6Buy1 Based on 8 Wall Street analysts who have issued ratings for Myriad Genetics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 1 has given a sell rating, 6 have given a hold rating, and 1 has given a buy rating for MYGN. Consensus Price Target $4.77-20.82% Downside According to the 8 analysts' twelve-month price targets for Myriad Genetics, the average price target is $4.77. The highest price target for MYGN is $8.00, while the lowest price target for MYGN is $3.00. The average price target represents a forecasted downside of -20.82% from the current price of $6.02. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for MYGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Myriad Genetics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Analyst Ratings Over TimeTypeCurrent Forecast10/26/25 to 10/26/261 Month Ago9/26/25 to 9/26/263 Months Ago7/28/25 to 7/28/261 Year Ago10/26/24 to 10/26/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)0 Buy rating(s)1 Buy rating(s)4 Buy rating(s)Hold6 Hold rating(s)4 Hold rating(s)4 Hold rating(s)8 Hold rating(s)Sell1 Sell rating(s)3 Sell rating(s)1 Sell rating(s)2 Sell rating(s)Consensus Price Target$4.77$3.12$6.50$12.45Forecasted Upside-20.82% Downside-25.18% Downside22.18% Upside52.82% UpsideConsensus RatingHoldReduceHoldHold MYGN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MYGN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Myriad Genetics Stock vs. The CompetitionTypeMyriad GeneticsHealthcare CompaniesBroader MarketConsensus Rating Score 2.00 2.32 2.53Consensus RatingHoldHoldModerate BuyPredicted Upside-20.82% Downside108.31% Upside16.61% UpsideNews Sentiment RatingNeutral NewsSee Recent MYGN NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/26/2024 - 10/26/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/20/2026 Wells Fargo & Company3 of 5 starsEvan StamplerNot RatedSet Target$4.50-18.77%10/20/2026 Piper Sandler2 of 5 starsDavid Westenberg5 of 5 starsUpgradeUnderweight ➝ Neutral$5.00-13.13%10/15/2026 Zacks Research4 of 5 stars UpgradeStrong Sell ➝ Hold10/13/2026 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankingsKyle BoucherSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetHold$4.00 ➝ $4.50+10.16%10/12/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeSell (E+) ➝ Sell (D-)10/2/2026 Craig HallumSubscribe to MarketBeat All Access to unlock brokerage rankingsJohn WilkinSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$4.00 ➝ $8.00+84.97%9/9/2026 UBS GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsLu LiSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageNeutral$6.00 ➝ $3.60+15.05%8/18/2026 StephensSubscribe to MarketBeat All Access to unlock brokerage rankingsMason CarricoSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetEqual Weight$5.00 ➝ $3.00-1.64%5/21/2025 ScotiabankSubscribe to MarketBeat All Access to unlock brokerage rankingsSung Ji NamSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00+34.83%5/8/2025 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsDoug SchenkelSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeOutperform ➝ Peer Perform Get the Latest News and Ratings for MYGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. 5/7/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsMatthew SykesSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetBuy$14.00 ➝ $8.00+72.82%5/7/2025 Raymond James FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsAndrew CooperSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOutperform$19.00 ➝ $10.00+108.77%4/9/2025 GuggenheimSubscribe to MarketBeat All Access to unlock brokerage rankingsSubbu NambiSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeBuy ➝ Neutral3/3/2025 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankingsDerik De BruinSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetUnderperform$13.00 ➝ $11.00+2.52%12/9/2024 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankings DowngradeOutperform ➝ Market Perform$30.00 ➝ $21.00+38.80%11/18/2024 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankings Lower TargetEqual Weight$32.00 ➝ $21.00+37.70%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:58 PM ET. MYGN Forecast - Frequently Asked Questions What is Myriad Genetics' forecast for 2026? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Myriad Genetics is $4.77, with a high forecast of $8.00 and a low forecast of $3.00. Should I buy or sell Myriad Genetics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There is currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. Does Myriad Genetics's stock price have much downside? According to analysts, Myriad Genetics's stock has a predicted downside of -20.82% based on their 12-month stock forecasts. Has Myriad Genetics been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Myriad Genetics's stock had 4 upgrades and 3 downgrades by analysts. What analysts cover Myriad Genetics? Myriad Genetics has been rated by research analysts at Craig Hallum, Piper Sandler, Stephens, TD Cowen, UBS Group, Weiss Ratings, Wells Fargo & Company, and Zacks Research in the past 90 days. Do Wall Street analysts like Myriad Genetics more than its competitors? Analysts like Myriad Genetics less than other "healthcare" companies. The consensus rating score for Myriad Genetics is 2.00 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how MYGN compares to other companies. Stock Forecasts and Research Tools Related Companies AGIO Stock Forecast VERA Stock Forecast SLS Stock Forecast VCEL Stock Forecast BCRX Stock Forecast LKFT Stock Forecast PHVS Stock Forecast IMNM Stock Forecast RXRX Stock Forecast SRPT Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Myriad Genetics RecommendationsWells Fargo & CompanyPiper SandlerZacks ResearchTD CowenWeiss RatingsCraig HallumUBS GroupStephensWall Street Zen MarketBeat monitors more than a dozen sources for Myriad Genetics analyst ratings, with the most recent rating issued on 10/20/2026. From Our PartnersNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
